comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 02:12:41 - browse：3554

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： What to know about the judge who will handle the Trump case

entertainment

leisure time

focus

WSS

AltruBio raises $225 million to develop ulcerative colitis drug

Empower primary care with adequate payments and technology

HHS's proposed rule does nothing to address the climate crisis

Primary care doctor shortage won't be solved by free med school tuition

Has Bernie Sanders reached the limit of his pharma bullying effort?

Mark Cuban is blaming the wrong people for high drug costs

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Novel spinal cord stimulator treats paralysis without surgery

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Virginia high school admissions case could be legal follow

Senators push IRS to launch nonprofit hospital probe

The high cost of giving birth even with insurance

Biogen’s boardroom scandal saddles CEO with first crisis

Trump demands the U.S. pay no more for drugs than other countries … again

Brain MRIs reveal impact of 'toxic stress' on Black children

knowledge

Schizophrenia gene found to be linked to cells' energy dysfunction

Most antidepressants don't work on kids, teens, study finds

Bird flu researchers hone in on Finland’s mink farms

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

AltruBio raises $225 million to develop ulcerative colitis drug

Deliver public health messages at the right time

entertainment

leisure time

focus

focus